Solifenacin: Nursing Drug Guide, Urinary Retention & NCLEX Review
Healthcare medication guide: urinary retention and kidney injury when bladder outlet obstruction is present, antimuscarinic dry mouth and constipation, long half-life dose accumulation, and why every voiding check matters after each solifenacin dose.
Like other antimuscarinic bladder drugs, VESICARE (solifenacin) can cause urinary retention and kidney injury—especially when clinically significant bladder outlet obstruction is present. The drug is contraindicated in urinary retention and not recommended with significant outlet obstruction (including advanced benign prostatic hyperplasia). With a half-life of approximately 45–68 hours, antimuscarinic effects—including confusion and somnolence—can persist and accumulate after dose increases. Monitor voiding, urine output, suprapubic status, and renal function on every shift; hold and escalate when retention is suspected.
📋 Contents
⚡ Quick facts
💡 Key takeaway
Before every dose, confirm the patient is voiding normally. In men with BPH, older adults, and anyone with low urine output, solifenacin can convert urge incontinence treatment into dangerous retention and kidney injury—hold, assess the bladder, and notify the team at the first sign of incomplete emptying.
Most common brand names
Solifenacin succinate is marketed as VESICARE (Astellas Pharma US, Inc.) in 5 mg and 10 mg film-coated tablets. Generic solifenacin succinate tablets are also available. Verify strength on the MAR—dose titration from 5 mg to 10 mg once daily is common when the starting dose is well tolerated.
Tablet identifiers per labeling: 5 mg round light yellow tablet debossed with 150; 10 mg round light pink tablet debossed with 151. Swallow whole with water; do not crush or split unless pharmacy confirms a specific product is safe to modify.
Why we give it — Indications
VESICARE is indicated for adults with overactive bladder with symptoms of urge urinary incontinence, urgency, and urinary frequency. It reduces uninhibited detrusor contractions to decrease leakage and voiding frequency.
| Use | Detail |
|---|---|
| Overactive bladder | Prescribing information lists treatment of urge incontinence, urgency, and frequency in adults. Clinical trials showed reduced micturitions per 24 hours and fewer incontinence episodes versus placebo. |
| Urge-predominant leakage | Nurses see solifenacin ordered when conservative measures fail for urinary incontinence driven by detrusor overactivity—not for stress incontinence alone. |
| Pediatric use | Safety and effectiveness in pediatric patients have not been established per labeling. |
On a small screen, swipe or scroll sideways to see the full table.
How it works
Solifenacin is a competitive muscarinic receptor antagonist. Muscarinic receptors mediate cholinergic contraction of urinary bladder smooth muscle; blocking them relaxes the detrusor, increases functional bladder capacity, and reduces urgency. Because antagonism is not organ-selective, systemic antimuscarinic effects occur: decreased salivation (dry mouth), decreased gastrointestinal motility and constipation, blurred vision, and central nervous system effects when concentrations rise.
In patients who already have difficulty emptying the bladder—such as significant outlet obstruction—reducing detrusor contractility can worsen incomplete bladder emptying, leading to retention and upstream kidney injury per labeling warnings.
Dosing overview
All dosing below reflects the VESICARE (solifenacin succinate) prescribing information. Confirm renal/hepatic function and interacting drugs before titrating to 10 mg.
Missed dose: Not specified in labeling. For once-daily therapy, do not double the next dose; give the usual dose at the next scheduled time unless the prescriber directs otherwise.
Onset, peak, duration, and half-life
| Parameter | Value | Nursing relevance |
|---|---|---|
| Absorption | Peak plasma concentration in 3–8 hours; ~90% bioavailability | Side effects may lag first dose; steady state takes days because of long half-life |
| Half-life | Approximately 45–68 hours with chronic dosing | Retention or CNS effects can persist days after the last dose—do not rush rechallenge without prescriber review |
| Food | May be taken with or without food; food minimally affects exposure | Consistent timing aids voiding-pattern comparison across shifts |
| Metabolism | Primarily CYP3A4; extensively hepatically metabolized | Strong CYP3A4 inhibitors require 5 mg cap; geriatric patients have 20–25% higher exposure |
| Elimination | ~69% urine, ~23% feces; <15% unchanged in urine | Renal impairment raises exposure—dose-limit in severe impairment |
On a small screen, swipe or scroll sideways to see the full table.
Before you give it — Safety check
Pretreatment checks
- Review voiding history, prior retention, BPH/BOO, and alpha-blocker therapy (e.g., tamsulosin) during medication reconciliation
- Screen for overlapping antimuscarinics (oxybutynin, diphenhydramine) that increase retention and CNS risk
- Confirm absence of urinary retention, gastric retention, uncontrolled narrow-angle glaucoma, and known hypersensitivity
- Verify renal and hepatic function support ordered dose; check for strong CYP3A4 inhibitors on MAR
Contraindications
- Urinary retention
- Gastric retention
- Uncontrolled narrow-angle glaucoma
- Hypersensitivity to solifenacin succinate or formulation components (anaphylaxis and angioedema reported)
Important interactions
| Drug / class | Effect | Nursing action |
|---|---|---|
| Strong CYP3A4 inhibitors (ketoconazole) | Mean Cmax and AUC increased ~1.5- and 2.7-fold; doses >5 mg not recommended | Verify dose cap; monitor for worsening dry mouth, constipation, retention, or confusion |
| Other antimuscarinic agents | Additive dry mouth, constipation, urinary retention, blurred vision, CNS effects | Reconcile duplicate bladder anticholinergics; hold overlapping therapy when toxicity suspected |
| QT-prolonging drugs | Labeling does not recommend solifenacin in patients at high QT prolongation risk | Flag history of QT prolongation or concurrent QT-prolonging therapy to prescriber/pharmacist |
On a small screen, swipe or scroll sideways to see the full table.
Administration
Route: Oral tablet once daily. Take with water and swallow whole. May be administered with or without food per labeling.
- Give at the same time each day to align nursing voiding checks across shifts
- Do not crush or chew tablets unless pharmacy verifies a specific product allows modification
- Pair administration with a quick voiding and mental-status check—especially within the first weeks and after titration to 10 mg
- Document strength (5 mg vs 10 mg) clearly on the MAR to prevent titration errors
Labeling reports somnolence and other antimuscarinic CNS adverse reactions. Advise patients not to drive or operate heavy machinery until they know how VESICARE affects them. Reinforce this after dose increases or when adding sedating co-medications.
Expected therapeutic response
- Fewer urgency episodes and reduced urinary frequency over days to weeks as steady state is reached
- Decreased urge incontinence episodes and improved interval between voids
- Increased volume voided per micturition without falling total daily urine output
- Manageable dry mouth or constipation without progressive retention, confusion, or rising creatinine
Clinical trials reported mean reductions in micturitions per 24 hours of 2.3 (5 mg) and 2.7 (10 mg) versus 1.4 with placebo at 12 weeks. Lack of bladder symptom improvement with declining urine output should prompt retention assessment—not automatic dose escalation.
Red flags — Stop and act
Urinary retention can develop quietly while urgency symptoms improve. Hold the dose and escalate when the following occur.
- Urinary retention: suprapubic pain or fullness, inability to void, anuria, or dribbling with distention—especially with BPH or prior incomplete emptying
- Rising creatinine or BUN on basic metabolic panel suggesting post-renal obstruction
- New or worsening confusion, hallucinations, delirium, or somnolence after initiation or dose increase
- Angioedema of face, lips, tongue, or larynx; difficulty breathing—discontinue immediately
- Signs of anaphylaxis or severe hypersensitivity after any dose
- Severe abdominal distention, absent bowel sounds, or ileus concern in patients with decreased GI motility
Adverse effects
| Adverse effect | Frequency / severity | Nursing response |
|---|---|---|
| Dry mouth, constipation | Most common (>4% vs placebo at 5 mg and 10 mg); higher at 10 mg | Oral care, bowel protocol, hydration; hold and notify if severe or paired with retention |
| Urinary retention | Reported in trials (up to 1.4% at 10 mg); postmarketing renal impairment | Monitor voiding and post-void residual; hold and escalate per retention pathway |
| Blurred vision, dry eyes | More frequent at 10 mg dose | Assess fall risk; notify prescriber if vision changes impair safety |
| UTI | More frequent at 10 mg in trials | Do not assume dysuria is only anticholinergic—evaluate for infection when clinically indicated |
| CNS: dizziness, headache, confusion, hallucinations, somnolence | Postmarketing and labeling warnings; monitor after dose changes | Hold drug, perform delirium assessment, notify prescriber for dose reduction or switch |
| Angioedema, anaphylaxis | Serious; may occur after first or later doses | Stop permanently; treat airway compromise per emergency protocol |
On a small screen, swipe or scroll sideways to see the full table.
Overdose, toxicity, and antidote
No specific antidote is listed. Overdosage can cause severe antimuscarinic effects and should be treated accordingly. Highest reported accidental ingestion was 280 mg over 5 hours with mental status changes.
Expected overdose findings
- Intolerable antimuscarinic effects: fixed and dilated pupils, blurred vision, tremor, dry skin
- Central nervous system depression or altered consciousness
- Urinary retention, ileus, tachycardia; QT prolongation reported postmarketing at therapeutic and supratherapeutic exposure
Treatment per labeling: gastric lavage and appropriate supportive measures; ECG monitoring recommended.
Contact local poison control or medical toxicology services for overdose guidance per facility protocol and local emergency guidance. Support airway, breathing, circulation, and cardiac monitoring as ordered.
Look-alike / sound-alike and error prevention
- Solifenacin vs silodosin vs tamsulosin—verify drug name and class; muscarinic antagonist vs alpha-blocker
- Solifenacin vs other bladder anticholinergics—duplicate muscarinic agents on one MAR increase retention risk; reconcile on admission
- VESICARE 5 mg vs 10 mg—similar tablet appearance with different deboss codes (150 vs 151); barcode scanning required
- Brand VESICARE vs generic name—ensure MAR reflects correct product during formulary switches
- Once-daily scheduling—do not place on twice-daily anticholinergic times copied from another drug
Practical bedside notes
| Topic | Bedside guidance |
|---|---|
| Crush/split | Swallow whole per labeling; consult pharmacy before crushing for enteral administration. |
| Long half-life | Effects persist 2–3 days after discontinuation—retention may not resolve immediately when drug is held. |
| Voiding checks | Palpate suprapubic area and trend I&O each shift; obtain bladder scan when retention suspected per protocol. |
| BPH overlap | Alpha-blocker therapy improves outlet resistance but does not remove retention risk when antimuscarinic is added—monitor closely. |
| Commonly missed | Automatic continuation of home solifenacin on admission without voiding assessment in men with known BPH. |
| Ask pharmacy when | CYP3A4 inhibitor started, renal/hepatic function changes, dose titration to 10 mg in impaired clearance, or retention suspected. |
On a small screen, swipe or scroll sideways to see the full table.
High-risk populations
| Population | Considerations |
|---|---|
| Clinically significant bladder outlet obstruction / BPH | Not recommended per labeling; may cause further retention and kidney injury. Coordinate with urology when bladder symptoms and obstruction coexist. |
| Geriatric patients | Exposure 20–25% higher than younger adults; similar efficacy in trials but monitor closely for retention and CNS effects. |
| Severe renal impairment (CLcr <30) | Maximum 5 mg once daily; 2.1-fold higher AUC—greater antimuscarinic adverse reaction risk. |
| Moderate hepatic impairment (Child-Pugh B) | Maximum 5 mg once daily; not recommended in Child-Pugh C. |
| Decreased GI motility | Not recommended; contraindicated in gastric retention—risk of worsened motility and ileus. |
| Pregnancy / lactation | No adequate human pregnancy data; use only if benefit outweighs risk. LactMed: no human breastfeeding data; long half-life favors alternate drug when possible. |
On a small screen, swipe or scroll sideways to see the full table.
Monitoring and documentation
Monitor
- Voiding pattern, urine output, suprapubic status, and retention signs—especially after titration to 10 mg
- Renal function (creatinine, BUN) when retention suspected or in patients with renal impairment
- Antimuscarinic effects: dry mouth severity, constipation, blurred vision, somnolence, confusion
- Bladder symptom response: urgency episodes, pad use, nocturia—balanced against emptying adequacy
Document
- Dose (5 mg vs 10 mg), time, route, and indication on MAR
- Baseline and follow-up voiding pattern; bladder scan results when performed
- Hold events with prescriber/pharmacist notification and alternative bladder plan
- Patient teaching on reporting inability to urinate, abdominal distention, confusion, and eye or throat swelling
Patient teaching
- Take once daily at the same time with water; swallow the tablet whole
- Dry mouth and constipation are common—increase fluids and fiber unless contraindicated; report severe constipation
- Report immediately: unable to urinate, painful full bladder, lower abdominal swelling, confusion, extreme drowsiness, eye pain, or swelling of face/tongue/throat
- Do not drive or use machinery until you know how this medicine affects you—somnolence is possible
- Tell all clinicians you take solifenacin before starting new medicines, especially antifungals or other bladder drugs
The Hold Rule
Do not give and contact the prescriber/pharmacist when:
- Urinary retention, anuria, or painful suprapubic distention with inability to void
- Rising creatinine or oliguria suggesting obstructive kidney injury
- New antimuscarinic CNS effects: confusion, hallucinations, delirium, or excessive somnolence
- Angioedema, anaphylaxis, or severe hypersensitivity
- Contraindicated conditions: gastric retention, uncontrolled narrow-angle glaucoma, known urinary retention
- Ordered dose exceeds limits for renal/hepatic impairment or strong CYP3A4 inhibitor co-therapy without pharmacy verification
Hold parameters may vary by institutional protocol. Follow prescriber orders, pharmacy guidance, and facility policy.
Clinical practice integration and workflow
Solifenacin is often started to control embarrassing urge symptoms—but in men with BPH and in frail older adults, the nurse must guard against trading incontinence for silent retention. Build voiding surveillance into every med pass because the long half-life means harm can accumulate before symptoms are obvious.
1. Check-before-you-give protocol
- Right patient, drug, dose (5 vs 10 mg), route, and once-daily time
- Last void time, urine output trend, and suprapubic assessment
- Renal dose limits when CLcr <30 or moderate hepatic impairment
- No duplicate antimuscarinic bladder agents or sedating antihistamines without prescriber intent
2. High-alert and safety badge
Not a traditional high-alert medication, but urinary retention with kidney injury is a high-stakes antimuscarinic safety issueTreat falling urine output on solifenacin with the same urgency as other obstruction red flags: hold, assess the bladder, notify, and document.
3. Clinical workflow: hold and question rules
- If urine output drops with suprapubic fullness, hold solifenacin and obtain bladder scan or catheterization per protocol
- If creatinine rises without other explanation, question retention and review BOO medications
- After titration to 10 mg, intensify voiding checks for 72 hours because of long half-life accumulation
4. Critical teach-back questions
- “What bladder symptoms mean you should call the care team right away?” (Patient should mention inability to urinate, painful fullness, or abdominal swelling.)
- “What side effects are common but what changes are dangerous?” (Patient should distinguish mild dry mouth from retention, confusion, or throat swelling.)
5. Care coordination
Pharmacist: Consult for renal/hepatic dose caps, CYP3A4 interaction checks, and alternative agents (e.g., beta-3 agonist) per formulary
Prescriber / urology: Notify for retention, rising creatinine, treatment failure, or intolerable antimuscarinic effects requiring dose reduction or drug change
🧠 Quick mental checklist
- When did this patient last void, and does the bladder feel distended?
- Is urine output trending down while solifenacin dose was recently increased?
- Does this patient have BPH, prior incomplete emptying, or another antimuscarinic on the MAR?
- Does renal function or hepatic impairment require a 5 mg cap?
- If retention is suspected, have I held the dose and notified the team?
Solifenacin NCLEX practice questions
Rehearse NCLEX-style clinical judgment practice for solifenacin using a tabbed case (MAR, labs, I&O, nursing notes), then work through priority action, retention cue recognition, renal trend interpretation, documentation cloze, ordered response, and matrix urgency sorting—recognise cues → analyse obstruction risk → prioritise → act → evaluate outcomes.
Select a tab to view MAR, labs, I&O, and nursing note details for this case.
- Solifenacin (VESICARE) 10 mg PO daily — given 0900; increased from 5 mg three days ago
- Tamsulosin 0.4 mg PO daily — given 0900
- Diphenhydramine 25 mg PO qHS PRN sleep — not given last two nights
- Home med list on admission included solifenacin 5 mg daily for OAB
- Admission BMP: creatinine 1.1 mg/dL, BUN 22 mg/dL
- Today BMP: creatinine 1.6 mg/dL, BUN 34 mg/dL
- Bladder scan (1400): post-void residual 420 mL (prior baseline 80 mL on day 1)
- Urinalysis: negative nitrites; no antibiotics started
- Intake today: 1,450 mL oral fluids
- Urine output: 180 mL since 0700 (patient usually produces 900–1,100 mL by this time)
- Last void documented: 0900 — 60 mL; patient reports “cannot go again”
- Suprapubic fullness noted on assessment at 1330
- 72-year-old male, admitted for cellulitis; history of BPH with long-standing nocturia
- Baseline: alert and oriented ×3; ambulates with walker
- 1200: Patient restless, pressing lower abdomen; denies fever
- 1345: Nurse reviewing MAR before evening care—solifenacin due tomorrow 0900
- Plan: assess retention risk before next scheduled dose
Answer key & rationale
Frequently asked questions
Why is urinary retention the main nursing danger with solifenacin?
VESICARE prescribing information states that like other antimuscarinic drugs, solifenacin in patients with clinically significant bladder outlet obstruction may cause further urinary retention and kidney injury. The drug is contraindicated in urinary retention and not recommended when outlet obstruction is clinically significant. Nurses must monitor voiding, urine output, suprapubic status, and renal function when retention is suspected.
When should a nurse hold solifenacin?
Hold and notify the prescriber or pharmacist for urinary retention or anuria, suprapubic pain with inability to void, rising creatinine suggesting kidney injury, new antimuscarinic CNS effects (confusion, hallucinations, somnolence), angioedema or anaphylaxis, uncontrolled narrow-angle glaucoma symptoms, or severe constipation or ileus. Solifenacin is contraindicated in urinary retention, gastric retention, and uncontrolled narrow-angle glaucoma.
What is the maximum solifenacin dose in renal or hepatic impairment?
Do not exceed 5 mg once daily in severe renal impairment (creatinine clearance less than 30 mL/min/1.73 m²) or moderate hepatic impairment (Child-Pugh B). VESICARE is not recommended in severe hepatic impairment (Child-Pugh C). With strong CYP3A4 inhibitors such as ketoconazole, do not exceed 5 mg once daily.
Can solifenacin be used with benign prostatic hyperplasia?
Labeling warns that solifenacin is not recommended in patients with clinically significant bladder outlet obstruction, including significant BPH-related obstruction. Alpha-blockers such as tamsulosin do not eliminate retention risk when an antimuscarinic is added. Monitor voiding pattern, post-void residual when ordered, and renal function closely.
Is there an antidote for solifenacin overdose?
No specific antidote is listed. Overdosage may cause severe antimuscarinic effects including mental status changes, fixed dilated pupils, blurred vision, tremor, and dry skin. Treatment is gastric lavage and supportive measures with ECG monitoring per prescribing information. Contact local poison control or toxicology services per facility protocol.
Can solifenacin be used during breastfeeding?
LactMed notes no published human breastfeeding experience and a long half-life averaging about 55 hours; an alternate drug may be preferred, especially while nursing a newborn or preterm infant. Long-term use might reduce milk production. Observe the infant for anticholinergic effects such as constipation, urinary retention, or dry mouth if the mother requires therapy.
References
-
U.S. National Library of Medicine. VESICARE (solifenacin succinate) tablet, film coated — Full prescribing information. DailyMed. Revised October 2022.https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9acee910-cdb2-4052-b8b3-c26aff1c8716
-
National Institute for Health and Care Excellence. Solifenacin. British National Formulary (BNF).https://bnf.nice.org.uk/drugs/solifenacin/
-
Drugs and Lactation Database (LactMed). Solifenacin. Bethesda (MD): National Institute of Child Health and Human Development; updated April 19, 2021.https://www.ncbi.nlm.nih.gov/books/NBK501669/
-
National Institute for Health and Care Excellence. Urinary incontinence and pelvic organ prolapse in women: management. NICE guideline NG123. 2019.https://www.nice.org.uk/guidance/ng123
-
U.S. Food and Drug Administration. MedWatch: FDA Safety Information and Adverse Event Reporting Program.https://www.fda.gov/safety/medwatch-fda-safety-information-and-adverse-event-reporting-program
Review and transparency
This medication guide is written and reviewed using NurseOnShift editorial and clinical review standards.
Educational use only. This content does not replace clinical judgment, prescriber orders, pharmacist guidance, product labeling, or institutional protocols.